Imagine trying to find a specific needle in a haystack, where the needle is a unique protein on a cancer cell. Current methods are like searching by hand for days using expensive tools. This technology acts like a high-powered magnet and a smart filter, quickly pulling out the exact targets needed to create a custom-made medicine for a patient.
Current neoantigen identification is too slow, expensive, and complex, limiting personalized immunotherapy to a few elite labs. This results in 60-80% of patients not responding to treatment.
A microfluidic immunopurification device combined with a peptide prioritization algorithm and mass spectrometry integration.
If you are an immunotherapy developer dealing with the fact that 60-80% of patients fail to respond to treatment — this project developed a microfluidic device and software that identifies the most relevant neoantigens to increase the chance of success.
If you are a clinic dealing with long and resource-demanding antigen identification processes — this project developed PeptiCHIP which provides rapid, accurate results using minimal sample amounts and lower costs.
If you are a research institute dealing with the lack of standard methods to identify antigens for autoimmune or infectious diseases — this project developed a platform that identifies relevant antigens without needing prior knowledge of their sequences.
Based on available project data, PeptiCHIP is designed to be low-cost and reduces the need for expensive laboratory equipment and consumables compared to current resource-demanding methods.
The project is currently in the pre-clinical validation and demonstration phase to generate evidence for investors and create a transition-to-market plan.
The IP was protected following a Proof of Concept at the University of Helsinki, and Valo Therapeutics holds full rights to develop, exploit, and commercialize the technology.
The project period runs from 2023-04-01 to 2025-09-30, focusing on pre-clinical validation and the transition-to-market plan.
PeptiCHIP integrates a microfluidic purification device with mass spectrometry analysis and a specific prioritization software to simplify the antigen profiling process.
The project is led by a single partner, Valo Therapeutics OY, a Finnish SME. With a 100% industry ratio, the project is streamlined for commercial exploitation, moving directly from a university-proven concept to a business-led pre-clinical validation phase.
Contact Valo Therapeutics OY in Finland
Contact us to explore licensing opportunities for PeptiCHIP technology.
